Why there is no validated KPV dose, schedule or protocol for people, how animal study amounts differ from human dosing, and what regulators say.
By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)
Short answer
There is no established human dosage of KPV. No dose-finding, pharmacokinetic or clinical study has been published, and FDA found no data on KPV given to people by any route [FDA briefing 2026]. Any KPV dosage chart, daily amount, protocol or timing schedule is therefore not based on clinical evidence.
Is there a KPV dosage chart, protocol or amount per day?
No. Charts, protocols and per-day amounts circulating online are not derived from any human study, because none exists. Questions about timing, such as morning or night, have also never been studied [FDA briefing 2026].
What a dose would require
For an approved medicine, a dose rests on evidence that KPV does not have:
Pharmacokinetics: how much reaches the blood and tissues, and how fast it is cleared. None exists for KPV in humans [FDA briefing 2026].
Nonclinical toxicology: the exposure at which harm appears in animals, used to set a safe starting point. No studies were identified [FDA briefing 2026].
Dose-ranging trials: different amounts compared in people for effect and tolerability. None has been registered or published.
A defined product: a characterised substance with impurity limits. FDA judged KPV not well characterised [FDA briefing 2026].
Why animal and cell amounts do not translate
Different forms. Studies used free acid, amide, acetylated or D-amino-acid analogues, and some changes altered activity about four-fold [Hiltz 1991].
Different delivery. A nanoparticle formulation produced effects at a concentration reported as 12,000 times lower than KPV in solution [Laroui 2010], so the amount depends on the carrier as much as on the peptide.
Non-linear responses. Several studies saw bell-shaped or biphasic dose responses, where more was not more effective [Haycock 2000].
Different exposure routes. Intestinal studies gave KPV in drinking water to mice [Dalmasso 2008]; skin studies used excised tissue [Pawar 2017]. Neither measures human absorption.
Regulatory context
In July 2026 FDA proposed not adding KPV to the list of substances pharmacies may compound, citing the absence of human safety and effectiveness data[FDA briefing 2026], and it lists KPV among substances that may present significant safety risks [FDA 2026]. The proposed products in that review were topical creams and gels, not injections. See regulatory status.
Frequently asked questions
Is there a KPV peptide dosage chart?
No validated one exists. A dose chart requires human pharmacokinetic and dose-finding studies, and none has been done for KPV. Charts circulating online are not based on clinical data.
How much KPV per day?
There is no established daily amount for people. FDA found no human data on KPV by any route of administration, so no amount has been shown to be effective or safe.
Should KPV be taken in the morning or at night?
Timing has never been studied in humans. Questions of timing presuppose a validated regimen, and none exists.
What is the half-life of KPV?
Unknown in humans. FDA found no human pharmacokinetic studies of KPV by any route, so its half-life, absorption and clearance in people have not been measured.
What doses did animal studies use?
Each study’s methods give the amounts used in its own model. They are experimental conditions for mice, rats or cells and cannot be converted into a human dose without human data.
Laroui H, Dalmasso G, Nguyen HT et al. (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. PubMed 19909746 · doi:10.1053/j.gastro.2009.11.003[Animal, grade C]
Hiltz ME, Catania A, Lipton JM (1991). Anti-inflammatory activity of alpha-MSH(11-13) analogs: influences of alteration in stereochemistry. Peptides. PubMed 1788140 · doi:10.1016/0196-9781(91)90131-8[Animal, grade C]
Haycock JW, Rowe SJ, Cartledge S et al. (2000). Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines. J Biol Chem. PubMed 10821844 · doi:10.1074/jbc.275.21.15629[In vitro, grade D]
Pawar K, Kolli CS, Rangari VK et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci. PubMed 28343991 · doi:10.1016/j.xphs.2017.03.017[Ex vivo, grade D]
U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]
U.S. Food and Drug Administration (2026-04-22). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Source[retrieved 2026-11-11]